SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
ArriVent disclosed Q2 2026 financial results (ended June 30, 2026) via press release on August 12, 2026, reporting a net loss of $93.2 million for the six-month period, cash and investments of $373.1 million, and cash runway extending into 2028.
View raw filing on EDGAR →This is a clear earnings release disclosing Lulu's Fashion Lounge's second quarter 2026 financial results for the period ended June 28, 2026, including net revenue of $67.8 million, net loss of $1.5 million, and Adjusted EBITDA of $1.0 million, along with reaffirmed full-year fiscal 2026 guidance. The press release is attached as Exhibit 99.1 and contains detailed financial statements and management commentary on operational performance.
View raw filing on EDGAR →MaxCyte issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing total revenue of $7.3 million, net loss of $8.9 million, and full-year 2026 guidance of $30–$32 million in revenue. The release includes unaudited condensed consolidated financial statements and management commentary on strategic developments including the Genentech partnership and SPL portfolio progress.
View raw filing on EDGAR →This is a standard earnings release disclosing Armata's financial results for Q2 2026 and six months ended June 30, 2026, furnished as Exhibit 99.1 under Item 2.02. The press release includes detailed financial statements (balance sheet, income statement), operational metrics, and clinical/regulatory milestones. The company reported Q2 net income of $74.1 million (driven by a $91.0 million non-cash gain on the Convertible Loan), increased cash position to $24.0 million, and significant progress on its AP-SA02 Phase 3 program including FDA Fast Track designation and pediatric study plan agreement.
View raw filing on EDGAR →This is a clear earnings release disclosing Energous Corporation's financial results for Q2 2026 and the six-month period ended June 30, 2026. The filing explicitly states "On August 12, 2026, Energous Corporation issued a press release announcing its financial results for the three and six months ended June 30, 2026" and furnishes the press release as Exhibit 99.1. The disclosure includes revenue ($3.1M for Q2, $6.2M for six months), gross profit, operating expenses, net loss, and per-share metrics, along with balance sheet and cash position data. The results show significant growth (217% revenue improvement YoY for Q2, 368% for six months) and represent a material milestone for the company, making this disclosure material to investors.
View raw filing on EDGAR →Battalion Oil Corporation disclosed its second quarter 2026 financial results, including quarterly operating revenues of $48.1 million, net income of $9.1 million ($0.34 per share), production volumes of 12,407 Boe/d, and adjusted EBITDA of $12.3 million, along with balance sheet and liquidity metrics as of June 30, 2026.
View raw filing on EDGAR →Park Dental Partners issued a press release on August 12, 2026 announcing its second quarter 2026 financial results for the period ended June 30, 2026. The disclosure includes detailed financial statements, revenue growth of 5.1% to $66.2 million, net income of $1.3 million, and updated full-year 2026 guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release furnished as Exhibit 99.1.
View raw filing on EDGAR →GMR Solutions Inc. issued a press release on August 12, 2026, announcing financial results for the three and six months ended June 30, 2026, including net revenue of $1,490.3 million (Q2 2026) and net loss of $28.3 million, along with reaffirmed full-year 2026 guidance. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →This exhibit is a press release announcing Belite Bio's unaudited second quarter 2026 financial results, including detailed income statements, balance sheet data, and operating metrics. The document explicitly states "Belite Bio Reports Unaudited Second Quarter 2026 Financial Results" and includes comprehensive financial tables showing net loss of $28.4 million for Q2 2026 and $55.4 million for the six-month period. This is a discrete earnings announcement, not a periodic financial report filing, and is material as it discloses significant operating losses and cash burn relevant to investor assessment.
View raw filing on EDGAR →Comscore issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $79.2 million (down 11.3% YoY), net loss of $14.8 million, and adjusted EBITDA of $1.3 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed financial metrics, segment performance, balance sheet information, and full-year 2026 guidance, all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →This is a press release disclosing Q2 2026 financial results for Titan Mining Corp, reporting record quarterly revenue of $25.7 million (up 57% year-over-year), net income of $5.4 million, and Adjusted EBITDA of $9.6 million (up 272% year-over-year). The document includes detailed operating metrics, financial tables, and forward guidance, which are hallmarks of an earnings release. Material to investors assessing the registrant's financial performance and operational trajectory.
View raw filing on EDGAR →This is a press release disclosing BrainsWay's Q2 2026 financial results, including revenue of $17.1 million (35% YoY growth), adjusted EBITDA of $3.5 million (141% YoY growth), and net income of $2.7 million. The company also raised full-year 2026 revenue and EBITDA guidance. The exhibit includes consolidated financial statements (balance sheet, income statement, cash flows) and reconciliation of non-IFRS measures, all hallmarks of a quarterly earnings release. Material to investors assessing operational performance and growth trajectory.
View raw filing on EDGAR →The filing discloses Arbutus Biopharma's second quarter 2026 financial results via a press release dated August 12, 2026, including revenue of $1.0 million, net loss of $5.1 million ($0.03 per share), and cash position of $92.6 million. This is a standard quarterly earnings release filed under Item 2.02 with financial statements and operational metrics, making it a material disclosure affecting investor assessment of the company's financial condition.
View raw filing on EDGAR →This is a press release announcing Stantec's Q2 2026 financial results, disclosing net revenue of $1.8 billion (up 11.5% YoY), adjusted EBITDA of $332.9 million (up 17.1%), and adjusted EPS of $1.61 (up 18.4%). The release also includes updated 2026 guidance with refined adjusted EBITDA margin targets and organic growth expectations. As a quarterly earnings announcement with detailed financial metrics and forward guidance, this is a classic earnings_release event that would materially affect a reasonable investor's assessment of the company's financial performance and outlook.
View raw filing on EDGAR →This is a press release announcing CAE's first quarter fiscal 2027 financial results, disclosing revenue of $1,173.4 million (up 6.8% YoY), EPS of $0.10 vs. $0.18 prior year, adjusted EPS of $0.26 (flat YoY), and free cash flow of $104.0 million. The document includes consolidated results, segment performance (Civil and Defense), cash flow metrics, and fiscal 2027 outlook. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →This is a press release announcing Allot Ltd.'s unaudited financial results for the second quarter of 2026, including revenue of $27.7 million (up 15% YoY), GAAP operating income of $1.1 million, and a raised full-year 2026 revenue guidance to $115–$118 million. The document contains consolidated balance sheets, statements of operations, cash flows, and GAAP-to-non-GAAP reconciliations typical of a quarterly earnings announcement. Material to investors as it discloses quarterly financial performance and updated forward guidance.
View raw filing on EDGAR →This exhibit is a press release announcing Ituran's second quarter 2026 financial results, with record revenue of $104.8 million (up 21% YoY), net income of $17.3 million (up 29% YoY), and EBITDA of $28.5 million (up 24% YoY). The document includes condensed consolidated financial statements (balance sheet, income statement, and cash flow statement) as of and for the periods ended June 30, 2026. This is a discrete earnings announcement, not a periodic financial report filing, and the results are material to investors assessing the registrant's financial performance and growth trajectory.
View raw filing on EDGAR →This is a press release announcing Global-e's Q2 2026 financial results, including GMV of $2,089 million (44% YoY growth), revenue of $299.0 million (39% YoY growth), and Adjusted EBITDA of $62.4 million (62% YoY growth). The company also raised full-year 2026 guidance across all metrics. The disclosure includes detailed financial metrics, business highlights, and forward-looking guidance typical of a quarterly earnings release.
View raw filing on EDGAR →This is a press release announcing Nexxen's Q2 2026 financial results, including record Contribution ex-TAC of $97.8 million (up 11% YoY), record programmatic revenue of $95.2 million (up 12% YoY), and all-time record quarterly CTV revenue of $37.8 million (up 33% YoY). The company also raised full-year 2026 guidance for the third time. The disclosure includes detailed financial highlights, operational metrics, and forward-looking guidance typical of an earnings release, making it material to investors' assessment of the company's financial performance and trajectory.
View raw filing on EDGAR →Annexon reported second quarter 2026 financial results, including R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M ($0.28 per share), with a cash position of $209.2M and anticipated runway into 2028.
View raw filing on EDGAR →This is a press release announcing Pharvaris' second quarter 2026 financial results, including Q2 2026 cash position (€318 million), R&D expenses (€35.0 million), G&A expenses (€15.8 million), and net loss (€47.8 million or €0.70 per share). The document explicitly states "announced financial results for the second quarter ending on June 30, 2026" and includes a "Second Quarter 2026 Financial Results" section with key financial metrics. While the release also contains business updates on clinical trials and a corporate promotion, the primary disclosure is the quarterly financial results, which is material to investors assessing the company's financial position and burn rate.
View raw filing on EDGAR →Performance Food Group issued a press release on August 12, 2026 announcing fourth-quarter and full-year fiscal 2026 financial results, including net sales of $67.8 billion (up 7.2%), net income of $359.3 million (up 5.6%), and Adjusted EBITDA of $1,929.4 million (up 9.2%), along with fiscal 2027 guidance. This is a standard earnings release disclosure under Item 2.02 that would materially affect a reasonable investor's assessment of the company's financial performance and outlook.
View raw filing on EDGAR →Lexeo Therapeutics issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including net losses of $25.9M and $46.1M respectively, R&D expenses of $19.0M and $34.7M respectively, G&A expenses of $9.0M and $15.6M respectively, and a cash position of $234.2M, along with material clinical program updates including SUNRISE-FA 2 initiation and RMAT designation for LX2020.
View raw filing on EDGAR →TScan Therapeutics issued a press release on August 12, 2026, announcing its financial results for the second quarter ended June 30, 2026, including revenue of $1.1 million, R&D expenses of $23.4 million, net loss of $30.4 million, and cash position of $100.2 million. The disclosure is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and operational highlights. This is material to investors assessing the company's financial condition and runway.
View raw filing on EDGAR →Sutro Biopharma issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing revenue of $9.8 million, net loss of $38.5 million, and cash position of $164.3 million, along with early clinical data from the STRO-004 Phase 1 study.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including collaboration and license revenue of $18.7 million, R&D expenses of $14.6 million, G&A expenses of $7.6 million, and a net loss of $6.4 million for the quarter, along with condensed consolidated balance sheets and statements of operations. The disclosure is material as it provides investors with the company's quarterly financial performance and cash runway guidance into Q1 2028.
View raw filing on EDGAR →This is a press release announcing Boyd Group Services Inc.'s second quarter 2026 financial results. The exhibit discloses quarterly sales of $1,013.7 million (up 29.9% year-over-year), Adjusted EBITDA of $135.9 million (up 44.9%), and Adjusted EBITDA margins expanding to 13.4% from 12.0%. The document includes detailed financial and operational highlights, management commentary from the CEO, and forward-looking guidance—all hallmarks of a quarterly earnings release. Material to investors as it reports significant revenue growth, margin expansion, and synergy realization from the Joe Hudson's acquisition.
View raw filing on EDGAR →This is a clear earnings release disclosing Avalyn Pharma's financial results for Q2 2026 (ended June 30, 2026), including R&D expenses ($24.7M), G&A expenses ($6.6M), net loss ($28.9M), and cash position ($413.5M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements and balance sheet data, which are typical of quarterly earnings announcements. Material to investors assessing the company's financial condition and cash runway.
View raw filing on EDGAR →The filing discloses flyExclusive's financial results for Q2 2026 and the first half of 2026 through a corporate presentation furnished as Exhibit 99.1. The presentation contains detailed financial metrics including consolidated revenue of $111 million (+22% YoY), gross profit growth of +65% YoY, and positive Adjusted EBITDA of $4.2M with a +954 basis point margin improvement. This is a classic earnings release disclosure under Item 2.02, presenting quarterly and year-to-date operating results and performance metrics to investors.
View raw filing on EDGAR →This is a clear earnings release disclosing Spruce Biosciences' financial results for Q2 2026 and the first six months of 2026, including cash position ($96.3M), R&D expenses ($12.2M for Q2), G&A expenses ($4.3M for Q2), and net loss ($16.2M for Q2, or $(6.68) per share). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial statements (condensed balance sheet and statements of operations) and material corporate updates regarding TA-ERT development milestones and leadership appointments.
View raw filing on EDGAR →Lumexa Imaging disclosed second quarter 2026 financial results via press release, reporting consolidated revenues of $264.2 million (5.1% increase year-over-year), net income of $2.7 million compared to a prior-year loss of $7.2 million, and updated full-year 2026 guidance.
View raw filing on EDGAR →Spire Global issued a news release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, including Q2 2026 revenue of $18.0 million, net loss of $20.0 million, and adjusted EBITDA of ($8.6) million, along with full-year 2026 revenue guidance of $75.0–$85.0 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the news release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes quarterly financial metrics, year-over-year and sequential comparisons, and forward-looking guidance, all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →Andersen Group Inc. issued a press release announcing financial results for the second quarter and six months ended June 30, 2026, reporting revenue of $217.7 million (Q2) and $458.4 million (six months), with adjusted net income of $39.0 million (Q2, up 38.8% YoY), and provided full-year 2026 guidance.
View raw filing on EDGAR →This is a clear earnings release disclosing Sera Prognostics' second quarter 2026 financial results, including revenue ($30,000), operating expenses ($10.0 million), and net loss ($9.1 million), along with condensed financial statements and business highlights. The filing explicitly states the press release was issued on August 12, 2026, announcing Q2 2026 results and is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.
View raw filing on EDGAR →Harmonic issued a press release on August 12, 2026 disclosing preliminary unaudited financial results for Q2 2026 (quarter ended July 3, 2026), including net revenue of $173.0 million, operating profit, and earnings per share. The company also raised its full-year 2026 outlook for Broadband revenue to $505-$525 million. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →This is a classic earnings release disclosure under Item 2.02. The company announced second quarter 2026 financial results on August 12, 2026, including net loss of $9.6 million (vs. $1.7 million in Q2 2025), zero revenue (vs. $14.2 million in Q2 2025), and detailed operating expense breakdowns. The press release is furnished as Exhibit 99.1 and includes condensed consolidated balance sheet and statements of operations. While the filing also covers business highlights (SP001 license agreement, Utebzi FDA approval, royalty financing, and CMO appointment), the Item 2.02 section is explicitly focused on financial results for the quarter ended June 30, 2026.
View raw filing on EDGAR →This is a clear earnings release disclosing Kura Oncology's second quarter 2026 financial results, including net product revenue of $9.1 million, collaboration revenue of $11.8 million, R&D expenses of $61.9 million, and a net loss of $68.3 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial statements and operational metrics for the quarter ended June 30, 2026.
View raw filing on EDGAR →Atara Biotherapeutics disclosed second quarter 2026 financial results on August 12, 2026, including revenue of $0.6 million, net loss of $4.8 million (or $0.32 loss per share), and cash position of $9.9 million. The press release titled "Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress" is furnished as Exhibit 99.1, with detailed condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release disclosing material financial results and cash runway guidance into mid-2027.
View raw filing on EDGAR →Acrivon issued a press release on August 12, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $17.964 million, R&D expenses of $13.844 million, and cash position of $90.0 million as of June 30, 2026. The filing includes condensed consolidated statements of operations and balance sheets, which are typical of a quarterly earnings disclosure. This is a standard Item 2.02 earnings release for a clinical-stage biotech company.
View raw filing on EDGAR →Coherent Corp. disclosed financial results for Q4 and full year fiscal 2026 ended June 30, 2026, reporting revenue of $2.05B (up 34% Y/Y), GAAP EPS of $1.19 (up $2.02 Y/Y), and non-GAAP EPS of $1.74 (up $0.74 Y/Y), along with forward guidance for Q1 FY2027.
View raw filing on EDGAR →This is a clear earnings release disclosing Atea's financial results for Q2 2026 (three and six months ended June 30, 2026), including operating expenses, net loss, cash position, and per-share metrics. The press release, furnished as Exhibit 99.1, announces "financial results for the second quarter ended June 30, 2026" alongside a business update on clinical trial progress. The financial tables show condensed consolidated statements of operations and balance sheet data, which are hallmarks of an earnings disclosure under Item 2.02.
View raw filing on EDGAR →RenovoRx issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $909,000 (61% sequential growth, 115% year-over-year growth), gross profit of $766,000 (84% margin), net loss of $2.9 million, and raising full-year 2026 revenue guidance to $3.75M–$4.25M. This is a standard quarterly earnings release with detailed financial statements and operational metrics, clearly falling under Item 2.02 disclosure of results of operations and financial condition.
View raw filing on EDGAR →First Tracks issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($168.0 million), R&D expenses ($25.6M and $59.6M), G&A expenses ($9.3M and $28.1M), and net loss ($33.4M and $83.9M). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational updates on clinical trial progress.
View raw filing on EDGAR →Identiv issued a press release on August 12, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $5.7 million, GAAP net loss of ($4.7) million, and non-GAAP adjusted EBITDA loss of ($2.7) million. The filing explicitly states "On August 12, 2026, Identiv, Inc. (the "Company") issued a press release announcing financial results for its second quarter ended June 30, 2026" and attaches the press release as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 ended June 30, 2026. Item 2.02 discloses Marchex's financial results including revenue of $11.0 million, net loss of $0.4 million, and adjusted EBITDA of $0.7 million, with the full earnings release furnished as Exhibit 99.1. The filing includes consolidated statements of operations and balance sheets, pro forma combined results following the Archenia acquisition, and forward-looking financial guidance for Q3 2026.
View raw filing on EDGAR →This is a clear earnings release disclosing Kailera's financial results for Q2 2026 (quarter ended June 30, 2026), filed on August 12, 2026. The press release reports R&D expenses of $101.1 million, G&A expenses of $20.3 million, and a net loss of $111.3 million for the quarter, along with cash position of $1,171.8 million. The disclosure includes both financial results and material business updates regarding clinical trial progress and executive appointments, which are typical components of a quarterly earnings release.
View raw filing on EDGAR →Leslie's issued a press release on August 12, 2026 announcing third quarter 2026 financial results for the period ended July 4, 2026, with detailed disclosure of sales ($458.5M, down 8.4%), gross profit, net income, EPS, and Adjusted EBITDA. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both quarterly and nine-month results with year-over-year comparisons.
View raw filing on EDGAR →This is a quarterly earnings release for 2Q26 (ended June 30, 2026) disclosing consolidated financial results including revenue of Ps. 26,037 million (38.7% growth), EBITDA of Ps. 960 million, and operational metrics such as 155 net new stores opened and same-store sales growth of 20.0%. The document explicitly states "2Q26 EARNINGS RELEASE" and presents detailed financial statements, management commentary, and cash flow analysis typical of a quarterly results announcement.
View raw filing on EDGAR →Fidelity Private Credit Fund disclosed results of operations and financial condition as of June 30, 2026 (Q2 2026), including portfolio metrics, performance data by share class, portfolio characteristics (loan-to-value, leverage, interest coverage, distribution rate), and market commentary in its quarterly investment strategy report.
View raw filing on EDGAR →This is a straightforward earnings release for Q2 2026 (three months ended June 30, 2026). The press release discloses net revenue of $44.1 million, operating income of $1.3 million, and net income of $84.3 million (driven by a $91.8 million non-cash gain on debt restructuring). The filing explicitly states "Beasley Broadcast Group, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026" and furnishes the press release as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures.
View raw filing on EDGAR →